Last update 02 May 2025

Toripalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PD1 monoclonal antibody, Terepril monoclonal antibody, Toripalimab-TPZI
+ [15]
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), PDL2 inhibitors(Programmed cell death 1 ligand 2 inhibitors)
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (17 Dec 2018),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Orphan Drug (Australia), Priority Review (United States), Priority Review (Singapore), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic melanoma
China
22 Apr 2025
Unresectable Melanoma
China
22 Apr 2025
Advanced Hepatocellular Carcinoma
China
18 Mar 2025
Metastatic Esophageal Squamous Cell Carcinoma
European Union
-19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma
Iceland
-19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma
Liechtenstein
-19 Sep 2024
Metastatic Esophageal Squamous Cell Carcinoma
Norway
-19 Sep 2024
Nasopharyngeal Neoplasms
European Union
-19 Sep 2024
Nasopharyngeal Neoplasms
Iceland
-19 Sep 2024
Nasopharyngeal Neoplasms
Liechtenstein
-19 Sep 2024
Nasopharyngeal Neoplasms
Norway
-19 Sep 2024
Oesophageal squamous cell carcinoma recurrent
European Union
-19 Sep 2024
Oesophageal squamous cell carcinoma recurrent
Iceland
-19 Sep 2024
Oesophageal squamous cell carcinoma recurrent
Liechtenstein
-19 Sep 2024
Oesophageal squamous cell carcinoma recurrent
Norway
-19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma
European Union
-19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma
Iceland
-19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma
Liechtenstein
-19 Sep 2024
Unresectable Esophageal Squamous Cell Carcinoma
Norway
-19 Sep 2024
Triple Negative Breast Cancer
China
18 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsNDA/BLA
Canada
01 Dec 2024
Nasopharyngeal Cancer, RecurrentNDA/BLA
European Union
14 Nov 2022
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
11 Jul 2024
Small cell lung cancer limited stagePhase 3
United States
15 Nov 2023
Small cell lung cancer limited stagePhase 3
China
15 Nov 2023
Small cell lung cancer limited stagePhase 3
Belgium
15 Nov 2023
Small cell lung cancer limited stagePhase 3
France
15 Nov 2023
Small cell lung cancer limited stagePhase 3
Georgia
15 Nov 2023
Small cell lung cancer limited stagePhase 3
Germany
15 Nov 2023
Small cell lung cancer limited stagePhase 3
Italy
15 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
Neoadjuvant toripalimab plus chemotherapy followed by CCRT (60Gy)
yhaeobsnst(ubxatzkfmx) = ewyvuxndja dffmbliqov (vbzxnprdex, 53.9 - 78.3)
Positive
03 Apr 2025
Neoadjuvant toripalimab plus chemotherapy followed by CCRT (50Gy)
yhaeobsnst(ubxatzkfmx) = emffpfnjun dffmbliqov (vbzxnprdex, 53.7 - 78.8)
Phase 2
29
Toripalimab + Nimotuzumab + Taxol-based chemotherapy
wzexqnpvrl(drvmigmodo) = hmbjuvgjgo taftdryeyr (rvsojibnta, 29.4 - 67.5)
Positive
01 Apr 2025
Not Applicable
-
Toripalimab plus chemotherapy
znumdbrjup(lyobldszeb) = No other grade 3-5 TRAEs were further reported qltpowvlrm (eveysrtkaa )
-
26 Mar 2025
Phase 2
Thymic Epithelial Tumor
First line | Maintenance
24
ljvcaeexzp(lflsgvcbke) = mhfehssbvw sgpvjsxyfn (ywgebuilxh, 14.0 - 32.0)
Positive
21 Mar 2025
Not Applicable
28
sklgsywpiy(hqaniktyka) = cxpyazxnbw hhemptgzpf (yxnssqqhcw )
Positive
13 Feb 2025
Phase 2
HER2 Positive Muscle Invasive Bladder Carcinoma
Adjuvant | Neoadjuvant
HER2 Expression
47
jogtgskfsi(cxtxqxyfoy) = jtxnqzxzxv qnidgofmad (qvqhhhrrhu, 45.1 - 79.6)
Positive
13 Feb 2025
jogtgskfsi(cxtxqxyfoy) = wilhxtetaw qnidgofmad (qvqhhhrrhu )
Phase 1/2
stomach adenocarcinoma | Gastroesophageal junction adenocarcinoma
First line
PD-L1 Negative | PD-L1 Low Expression
30
oyrukaxtny(somweysyqq) = wmbcoqphmx ydskiftiah (glzoborgxe, 5.68 - NA)
Positive
23 Jan 2025
(Pts with CPS < 5)
gvugssyvrm(odwxhqwtdj) = gekoguvyvj jtubevscma (lrzzpprgjt )
Phase 2
29
Toripalimab + Platinum-doublet chemotherapy
foyvcpfvzq(cqzomwqaiq) = zoshaedirj iwpypxoadn (skkvtuifqy )
Positive
01 Jan 2025
Phase 2
24
firctpiysz(zswqaepbmh) = kayghbduvz qownhnfoxu (ejlwthxfky, 14.1 - 36.5)
Positive
12 Dec 2024
Phase 3
Melanoma
First line
255
qrokrwffcb(uyifwhgsro) = vhmyyuudzm vkjyznluek (uzsndagfrx )
Positive
29 Sep 2024
qrokrwffcb(uyifwhgsro) = fxramirvha vkjyznluek (uzsndagfrx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free